These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20011529)

  • 1. Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
    Hodel EM; Kabanywanyi AM; Malila A; Zanolari B; Mercier T; Beck HP; Buclin T; Olliaro P; Decosterd LA; Genton B
    PLoS One; 2009 Dec; 4(12):e8184. PubMed ID: 20011529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania.
    Gallay J; Pothin E; Mosha D; Lutahakana E; Mazuguni F; Zuakulu M; Decosterd LA; Genton B
    PLoS One; 2018; 13(9):e0202745. PubMed ID: 30192770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
    Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
    Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for sulfadoxine-pyrimethamine resistant malaria parasites in the Lake and Southern Zones, Tanzania, using pooling and next-generation sequencing.
    Ngondi JM; Ishengoma DS; Doctor SM; Thwai KL; Keeler C; Mkude S; Munishi OM; Willilo RA; Lalji S; Kaspar N; Kitojo C; Paxton LA; Hathaway NJ; Bailey JA; Juliano JJ; Meshnick SR; Gutman J
    Malar J; 2017 Jun; 16(1):236. PubMed ID: 28583119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out.
    Raman J; Mauff K; Muianga P; Mussa A; Maharaj R; Barnes KI
    PLoS One; 2011; 6(10):e25992. PubMed ID: 22022487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
    Esu E; Berens-Riha N; Pritsch M; Nwachuku N; Loescher T; Meremikwu M
    Malar J; 2018 Jul; 17(1):251. PubMed ID: 29976228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined antimalarial therapy using artemisinin].
    Majori G
    Parassitologia; 2004 Jun; 46(1-2):85-7. PubMed ID: 15305693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study.
    Zurovac D; Ndhlovu M; Rowe AK; Hamer DH; Thea DM; Snow RW
    BMJ; 2005 Oct; 331(7519):734. PubMed ID: 16195289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.
    Mayxay M; Khanthavong M; Lindegårdh N; Keola S; Barends M; Pongvongsa T; Yapom R; Annerberg A; Phompida S; Phetsouvanh R; White NJ; Newton PN
    Clin Infect Dis; 2004 Oct; 39(8):1139-47. PubMed ID: 15486837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to subsidized artemether-lumefantrine from the private sector among febrile children in rural setting in Kilosa, Tanzania.
    Simba D; Kakoko D
    Tanzan J Health Res; 2012 Apr; 14(2):89-95. PubMed ID: 26591729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health workers perceptions on chloroquine and sulfadoxine/sulfalene pyrimethamine monotherapies: implications for the change to combination therapy of artemether/lumefantrine in Tanzania.
    Tarimo DS; Malekela DA
    East Afr J Public Health; 2007 Apr; 4(1):43-6. PubMed ID: 17907761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea.
    Genton B; Baea K; Lorry K; Ginny M; Wines B; Alpers MP
    P N G Med J; 2005; 48(3-4):141-50. PubMed ID: 17212060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
    Gosling RD; Gesase S; Mosha JF; Carneiro I; Hashim R; Lemnge M; Mosha FW; Greenwood B; Chandramohan D
    Lancet; 2009 Oct; 374(9700):1521-32. PubMed ID: 19765815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors for the uptake of optimal doses of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Tanzania: further analysis of the data of the 2015-2016 Tanzania demographic and health survey and malaria indicator survey.
    Mushi V; Mbotwa CH; Zacharia A; Ambrose T; Moshi FV
    Malar J; 2021 Feb; 20(1):75. PubMed ID: 33549094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.
    Hodel EM; Zanolari B; Mercier T; Biollaz J; Keiser J; Olliaro P; Genton B; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):867-86. PubMed ID: 19249251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.
    Peters PJ; Thigpen MC; Parise ME; Newman RD
    Drug Saf; 2007; 30(6):481-501. PubMed ID: 17536875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saleability of anti-malarials in private drug shops in Muheza, Tanzania: a baseline study in an era of assumed artemisinin combination therapy (ACT).
    Ringsted FM; Massawe IS; Lemnge MM; Bygbjerg IC
    Malar J; 2011 Aug; 10():238. PubMed ID: 21843328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia.
    Osorio LE; Giraldo LE; Grajales LF; Arriaga AL; Andrade AL; Ruebush TK; Barat LM
    Am J Trop Med Hyg; 1999 Dec; 61(6):968-72. PubMed ID: 10674680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.
    Mutabingwa T; Nzila A; Mberu E; Nduati E; Winstanley P; Hills E; Watkins W
    Lancet; 2001 Oct; 358(9289):1218-23. PubMed ID: 11675058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies.
    Mugittu K; Abdulla S; Falk N; Masanja H; Felger I; Mshinda H; Beck HP; Genton B
    Malar J; 2005 Nov; 4():55. PubMed ID: 16297234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.